Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repros fibroids drug improves symptoms
This study compared two doses of Proellex, 12.5mg and 25mg, to placebo. The study's primary endpoint was reduction in excessive menstrual bleeding, a common symptom of uterine fibroids.
This study compared two doses of Proellex, 12.5mg and 25mg, to placebo. The study's primary endpoint was reduction in excessive menstrual bleeding, a common symptom of uterine fibroids.
The study involved people with Parkinson's disease who weren't responding optimally to the widely used treatment for Parkinson's, levodopa. For the study, half of the group took GlaxoSmithKline's
Acomplia is indicated in association with a light hypocaloric diet and physical activity for obese patients, or for overweight patients with at least one associated cardiovascular risk factor.
Alpha-1-antitrypsin deficiency, also known as AATD or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein AAT. AATD is also the most common
The objective of the study is to confirm naproxcinod's efficacy and provide additional blood pressure data, a key factor to differentiate naproxcinod from existing treatments. The company also
The studies were designed to examine the efficacy and safety of three inhaled doses each of the compound over 14 days in patients with asthma who were controlled
The agency has also indicated to Genelabs that a positive outcome to the proposed new phase III study in addition to evidence of efficacy from previous trials of
Both settlements cover activities that occurred at Pharmacia before that company was acquired by Pfizer in 2003. The subsidiaries have agreed to pay fines totaling $34.7 million. One
As part of their recently signed agreement, Ranbaxy will be able to progress and further profile this drug candidate through preclinical studies needed to support an investigational new
Novavax's vaccine was tested in three animal models, including the ferret, which is the most predictive model for influenza vaccine effectiveness in humans. Protection, as measured by a